Cite
HARVARD Citation
Pallett, S. et al. (2022). 4 Early identification of high-risk individuals for combination monoclonal antibody therapy is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay. BMJ military health. 168 (5), p. e1. [Online].